I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S.

ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program ...

The supervisory board of the Company has reviewed the financial statements 2024 on April 2nd, 2025 and the Company's ...

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

Solid Biosciences Inc.’s SLDB share price has dipped by 14.97%, which has investors questioning if this is right time to buy.

Former IPL winner Ambati Rayudu has shared his insights on Mumbai Indians (MI) IPL campaign so far and what they could do to ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 10.67%, which has investors questioning if this is right time ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Analysts Michael van de Poppe and Rekt Capital remain optimistic about the Bitcoin price's bullish future, predicting a ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...

Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; ...